2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Serologic Tests, Bioinformatics, Clinical Procedures, Computational Biology, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, CHIP, Genomics, Immune Mechanism, Metabolism, Microbiome, Molecular Biology, Clinical Practice (Health Services and Quality), Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Myeloid Malignancies, Measurable Residual Disease, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly
PAPER

4064 Blood-based longitudinal MRD monitoring by clonotypic peptide mass spectrometry in transplant-ineligible newly diagnosed multiple myeloma: Results from the imroz trial

Luciano Di Stefano, PhD, Victor Vimard2, Zarouki Mouktadi, MSc3, Vincent Bonifay, PhD4, Corina Oprea5, Rick Zhang, PhD6, Hongfang Wang, PhD7, Sandrine Macé8, Zandra Klippel, MD9, Caroline Rouge Dubroc, PharmD10
1 Sebia, Évry, France
2 Sebia, Évry, France
3 Sebia, Évry, France
4 Sebia, Évry, France
5 Sanofi, Vitry-sur-Seine, France
6 Sanofi, Vitry-sur-Seine, France
7 Sanofi, Vitry-sur-Seine, France
8 Sanofi, Vitry-sur-Seine, France
9 Sanofi, Vitry-sur-Seine, France
10 Sebia, Évry, France

Background:

Serum M-protein monitoring is a cornerstone of multiple myeloma response assessment, yet standard electrophoretic methods have limited sensitivity for tracking deep residual disease and subtle kinetic changes during prolonged follow-up. While bone marrow MRD assays remain highly informative, their invasive nature and discrete sampling limit their ability to capture continuous disease dynamics. M-InSight® (Sebia) has already shown strong clinical utility as a sensitive, patient-specific blood-based mass spectrometry assay for longitudinal M-protein monitoring and MRD assessment. Here, we expanded the clinical evaluation of M-inSight® in the IsaVRd arm of IMROZ study (NCT03319667), assessing serial M-protein kinetics, the magnitude of change, and exploratory blood-based MRD negativity across long-term follow-up.

 

Methods:

The IMROZ study is a phase 3 randomized trial comparing isatuximab plus VRd (Isa-VRd) with VRd in transplant-ineligible patients with newly diagnosed multiple myeloma. The depth and durability of responses observed with Isa-VRd make this cohort well suited to investigate the clinical utility of M-inSight®. Serum samples from 194 patients treated within IsaVRd arm were analyzed longitudinally from baseline through serial follow-up timepoints up to 60 months. From a baseline serum sample, the M-protein sequence and the patient-specific clonotypic peptides were identified. Follow-up serum samples were quantified by high-resolution LC-MS/MS, and M-protein concentrations were reported in mg/L. M-InSight® negativity was defined using a pre-defined serum M-protein cutoff. For the 12-month analysis, one sample per patient was selected within a ±4-month window around month 12, prioritizing the sample closest to month 12; when two samples were equally distant, the later sample was selected.

 

Results:

The dataset included 1,092 serum samples from 194 patients. Median baseline M-protein concentration was 27 g/L. M-protein concentrations declined rapidly during follow-up, with median reductions from baseline of 98.7% at cycle 6, 99.7% at cycle 12, 99.9% at cycle 18, and 99.9% at cycle 24 among patients with paired baseline and follow-up samples. Using a the pre-defined threshold, visit-level M-InSight® negativity increased from 12/92 samples at C6 (13.0%) to 24/74 at C12 (32.4%), 28/57 at C24 (49.1%) and 19/36 at C48 (52.8%). At the patient level, 115/194 patients reached M-InSight® negativity at least once during follow-up. At the patient level, 115/194 patients (59.3%) achieved M-InSight® negativity at least once during available follow-up. Using the full cohort denominator, cumulative first negativity increased from 17/194 patients by C6 to 43/194 by C12, 79/194 by C24 and 113/194 by C60.

To increase evaluability around the clinically relevant 12-month landmark, a ±4-month window analysis was performed. This identified one evaluable sample for 167/194 patients (86.1%). In this window, median M-protein concentration was 66.8 mg/L, and 49/167 patients (29.3%) were below the cut-off. Despite many patients remaining above the cut-off at this timepoints, most had already achieved profound biochemical reduction: 156/167 patients (93.4%) had >90% M-protein reduction from baseline, and 113/167 patients (67.7%) had >99% reduction.

Conclusions:

Longitudinal clonotypic peptide mass spectrometry enabled highly sensitive, patient-specific monitoring of serum M-protein kinetics across a large multiple myeloma cohort. M-protein levels declined profoundly over time, with increasing rates of blood-based negativity during extended follow-up. A 12-month ±4-month window substantially improved evaluability and showed that many patients had deep M-protein reduction even while remaining detectable above the cut-off. These findings demonstrate that longitudinal blood-based monitoring by M-inSight® can sensitively track treatment response in multiple myeloma. Beyond binary negativity assessments, dynamic changes in serum M-protein levels may be more informative, enabling more frequent and less burdensome monitoring. This approach has the potential to expand access to MRD-informed disease management while reducing reliance on repeated bone marrow evaluations.

Vincent Bonifay, PhD: SEBIA - Current Employment